1. How Can We Improve Cardiovascular Risk Reduction in Statin-Intolerant Patients?

2. Statin Myopathy (AHA/ACC/NHLBI)

3. Incidence of Muscle Adverse Effects

4. Differences Among Statins?

5. Reports of Myotoxicity in Major Randomized Trials Using Maximum-dose Statins

6. PRIMO: Patient Cohort

7. PRIMO: Risk of Muscular Symptoms With Individual Statins

8. Timing of Myalgia in PRIMO

9. Mechanisms of Statin-Induced Myopathy and Rhabdomyolysis

10. Factors That Increase the Risk of Statin-Induced Myopathy

11. Coenzyme Q10 Supplementation for the Treatment of Statin Associated Myopathy

15. GAUSS: Phase 2 AMG 145 in Statin-Intolerant Patients

16. GAUSS: Baseline Characteristics

17. GAUSS: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

18. GAUSS: Percentage of Patients Achieving LDL-C Goals

19. Summary

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)

26. References (cont)